This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

NeoStem Expands Treg International Patent Portfolio With Granting Of Patent In Japan

Stocks in this article: NBS

NEW YORK, Feb. 4, 2014 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy industry, today announced the expansion of intellectual property protection surrounding the Company's T-regulatory cell ("Treg") program with the grant of Japanese Patent Number 5409827 titled "Methods for the Isolation and Expansion of Cord Blood Derived T Regulatory Cells." This grant further expands the scope and reach of NeoStem's Treg patent estate internationally.

Through its Treg program, NeoStem is developing therapies that restore immune balance by enhancing regulatory T cell number and function. NeoStem's novel approach is being advanced by collaborations with leading research teams in the field of T cell therapy, including a collaboration with the University of California, San Francisco, and the laboratories of Drs. Jeffrey Bluestone and Qizhi Tang. NeoStem has a broad patent estate covering the Treg program, including over 30 issued patents and patent applications in U.S. and major international markets.

In November 2013, Japan enacted the Regenerative Medicine Law and passed revisions to the Pharmaceutical Affairs Law, providing opportunities to accelerate the development of regenerative medicines in Japan.

"We are excited to have received this patent issuance and about the recent changes in Japan which signal Japan's commitment to regenerative medicine. We look forward to exploring opportunities in Japan within the new regulatory framework to develop our regenerative medicine products in Japan and to bringing these important products to the market to meet the health needs of the Japanese people," said Dr. Robin L. Smith, Chairman and CEO of NeoStem.

In addition, these new Japanese regulations should be meaningful in allowing NeoStem to accelerate time to market in Japan for its cardiovascular disease program, for which NeoStem has already been granted related patent protection in Japan, should the Company pursue clinical development there.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs